Shares of Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN – Get Free Report) have received a consensus rating of “Moderate Buy” from the six research firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $55.00.
Several equities research analysts have recently issued reports on SLN shares. Weiss Ratings restated a “sell (d-)” rating on shares of Silence Therapeutics in a report on Friday, July 17th. Cantor Fitzgerald started coverage on Silence Therapeutics in a research report on Wednesday, June 24th. They set an “overweight” rating on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $75.00 price target on shares of Silence Therapeutics in a research note on Wednesday, June 17th.
Read Our Latest Research Report on Silence Therapeutics
Silence Therapeutics Stock Performance
Silence Therapeutics (NASDAQ:SLN – Get Free Report) last issued its quarterly earnings results on Friday, May 8th. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.14). Silence Therapeutics had a negative net margin of 8,943.86% and a negative return on equity of 105.34%. The business had revenue of $0.42 million during the quarter, compared to analyst estimates of $1.25 million. As a group, equities analysts predict that Silence Therapeutics will post -1.08 EPS for the current year.
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the stock. XTX Topco Ltd purchased a new stake in Silence Therapeutics in the fourth quarter valued at approximately $71,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Silence Therapeutics by 65.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 13,653 shares of the company’s stock valued at $83,000 after purchasing an additional 5,421 shares during the last quarter. Citadel Advisors LLC acquired a new position in shares of Silence Therapeutics in the 3rd quarter valued at $112,000. Massar Capital Management LP purchased a new stake in shares of Silence Therapeutics during the 2nd quarter valued at $115,000. Finally, GAMMA Investing LLC grew its stake in shares of Silence Therapeutics by 18.1% during the 2nd quarter. GAMMA Investing LLC now owns 11,063 shares of the company’s stock valued at $121,000 after buying an additional 1,698 shares during the period. 98.73% of the stock is currently owned by hedge funds and other institutional investors.
About Silence Therapeutics
Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.
The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.
Featured Stories
- Five stocks we like better than Silence Therapeutics
- SpaceX: Love the Company, But the Stock Is a Harder Call
- Ulta’s Growth Is Real, But So Are the Risks
- BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story
- Meta’s Earnings Drop Shows Wall Street Wants More Than Ad Growth
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
